Neximmune Inc (NEXI)
$1.34
Performance
- $1.32$1.38$1.34
1.49%
Downside
Day's Volatility :4.66%
Upside
3.21%
- $1.25$28.69$1.34
6.72%
Downside
52 Weeks Volatility :95.64%
Upside
95.33%
Returns
| Period | Neximmune Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -59.05% | 6.5% | 0.0% |
6 Months | -74.21% | 7.1% | 0.0% |
1 Year | -80.27% | 9.8% | 0.0% |
3 Years | -99.52% | 14.2% | -20.2% |
Highlights
Market Capitalization | 2.2M |
Book Value | $2.0 |
Earnings Per Share (EPS) | -24.11 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -69.71% |
Return On Equity TTM | -196.48% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -21.2M |
Diluted Eps TTM | -24.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 49.25%
Technicals Summary
Sell
Neutral
Buy
Neximmune Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Neximmune Inc | -50.0% | -74.21% | -80.27% | -99.52% | -99.78% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Neximmune Inc | 0.01 | NA | NA | 0.0 | -1.96 | -0.7 | NA | 2.0 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Neximmune Inc | Buy | $3.3M | -99.78% | 0.01 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Neximmune Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 141.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 286.0%
Institutional Holdings
Sabby Management LLC
4.37%Slate Path Capital LP
2.70%EPIQ Capital Group, LLC
1.14%PNC Financial Services Group Inc
0.92%Vanguard Group Inc
0.88%Raymond James & Associates
0.79%
Company Information
neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Organization | Neximmune Inc |
Employees | 6 |
CEO | Ms. Kristi Jones R.Ph. |
Industry | Healthcare |
